Hugel America, Inc. Announces U.S. FDA Acceptance of Biologics License Application (BLA) for LetibotulinumtoxinA for Injection to Treat Glabellar (Frown) Lines

NEWPORT BEACH, Calif.: NEWPORT BEACH, Calif., June 15, 2021 /PRNewswire/ -- Hugel America, Inc., a growth focused joint venture between aesthetic market-leading partners Hugel Inc., and Croma-Pharma GmbH, today announced that the Biologics License Application (BLA) for LetibotulinumtoxinA for Injection, to treat moderate to severe glabellar (frown) lines in adult...

Click to view original post